Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial - sprookjes - yvandenbroek - TriplyDB

Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial

Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial

http://www.wikidata.org/entity/Q28294837

about

Aflibercept for neovascular age-related macular degeneration Aflibercept for neovascular age-related macular degeneration Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration Anti-vascular endothelial growth factor for neovascular age-related macular degeneration Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration Association of Anti-VEGF Injections with Progression of Geographic Atrophy Management of Neovascular Age-related Macular Degeneration: A Review on Landmark Randomized Controlled Trials Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration The Emerging Regulation of VEGFR-2 in Triple-Negative Breast Cancer Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration Effects of Vitreomacular Adhesion on Age-Related Macular Degeneration Anti-VEGF Therapy and the Retina: An Update Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept Treatment as Required versus Regular Monthly Treatment in the Management of Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis Individualized Treatment of Neovascular Age-Related Macular Degeneration: What are Patients Gaining? Or Losing?Management of neovascular age-related macular degeneration: current state-of-the-art care for optimizing visual outcomes and therapies in development Endothelial progenitor cells in diabetic retinopathy Comparative safety and tolerability of anti-VEGF therapy in age-related macular degeneration Myopic choroidal neovascularisation: current concepts and update on clinical management Combined intravitreal anti-VEGF and photodynamic therapy versus photodynamic monotherapy for polypoidal choroidal vasculopathy: a systematic review and meta-analysis of comparative studies Aflibercept in wet AMD beyond the first year of treatment: recommendations by an expert roundtable panel The safety of intravitreal bevacizumab monotherapy in adult ophthalmic conditions: systematic review The design and implementation of a study to investigate the effectiveness of community vs hospital eye service follow-up for patients with neovascular age-related macular degeneration with quiescent disease.Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials Geographic Atrophy and Choroidal Neovascularization in the Same Eye: A Review Ranibizumab for age-related macular degeneration: a meta-analysis of dose effects and comparison with no anti-VEGF treatment and bevacizumab The Vascular Endothelial Growth Factor Inhibitors Ranibizumab and Aflibercept Markedly Increase Expression of Atherosclerosis-Associated Inflammatory Mediators on Vascular Endothelial Cells SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.Demographics of patients receiving Intravitreal anti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials.Present and possible therapies for age-related macular degeneration.An introduction to patient-reported outcome measures in ophthalmic research.A prospective study of treatment patterns and 1-year outcome of Asian age-related macular degeneration and polypoidal choroidal vasculopathy.Ranibizumab versus bevacizumab for ophthalmic diseases related to neovascularisation: a meta-analysis of randomised controlled trials.A glimpse at the aging eye.Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial.Drug treatment of macular oedema secondary to central retinal vein occlusion: a network meta-analysis.Switching to less expensive blindness drug could save medicare part B $18 billion over a ten-year period Reducing the clinical burden of ranibizumab treatment for neovascular age-related macular degeneration using an individually planned regimen.Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA).Insulin-like growth factor-1 and anti-vascular endothelial growth factor in retinopathy of prematurity: has the time come?

P2860

Q24186157-61481ADF-E95D-467D-98EB-575562A39CFD Q24193255-3892A8DC-563E-4BF9-8AC8-F6F27978F230 Q24193614-4662E744-A00E-4C6D-9D99-FE03C38BB429 Q24194251-99F4EE71-D04C-4773-8181-CA5E7F4CEC76 Q24195003-64A5DA2D-B2B0-4A50-8813-E2767D31021F Q26741294-B640FD77-F675-4588-9F7F-60357CF56A8D Q26767095-128B8E6F-C630-44F5-82B5-FEAB54404807 Q26771522-6776E816-7718-49C1-A541-30C73403D7C1 Q26779248-1BAC4950-42A0-47C3-9A5B-54C70834F8F6 Q26780543-9E08EB97-1525-45C2-9366-024A4659CD6E Q26783389-47AE836D-8460-4B76-9F47-DDEF8A3E6D41 Q26784605-1923E9C6-F389-4B13-A963-4E475B66ADA8 Q26786766-0B41AE14-A999-4A1E-818C-5BA502447D31 Q26787156-3D40BD7F-49FF-46C3-A6A2-6DED3943EFEF Q26799492-9289F189-653F-4E0D-B4F8-D9F02EDDEFAC Q26824335-DC58ABCC-79B3-48D0-A493-2DDC9DE94625 Q26827206-8CF83132-6485-4C09-90EC-7D118FCB929B Q26852289-E8CBFA42-DF0F-4E84-B5C4-010124C202EE Q26865884-C2016AF9-8865-4E38-B3EB-94BBAB8C4F5D Q26995216-7FD066FA-EC45-4556-8AA9-3A65DC2D7A9A Q26999836-2D45A002-556C-4694-80EC-09EADF7844D2 Q27013836-FE679015-86A5-4C6C-8BC8-B112AF9E665F Q27324293-91088914-C135-472B-A756-9D16DA06781F Q28049700-3983E189-6C31-4D9F-9819-1BE41A03CFA0 Q28074640-2692131B-24C7-4E24-8511-E5389F8449C0 Q28236004-DAAFF5BB-3CA6-4A36-99BA-04B29A9BBBEF Q28550616-79F51EA5-1712-4996-AC60-AFEE73621A86 Q30490738-D6AB3584-48CA-422A-A20B-631C0BC4A642 Q31155420-19035800-224F-432D-81D7-988CAE511EE3 Q33562731-CD282F54-C105-40E2-913E-44A09C1E5E4A Q33759121-6A116799-3947-4C6C-BBF6-7EF54FD7D414 Q33825750-1A5423D0-F524-42D7-9D3A-B72A67D9DD87 Q33830753-187709B2-0EF3-42B4-9379-D77CE262D6B6 Q33914344-108484E1-2298-4CC9-B21E-A942C6703053 Q33995880-9A570FDF-FD87-4E4B-83B7-ECD7158DF3BE Q33995887-4D87FD13-DDB0-489C-AAD1-89EF9E8E0123 Q34062494-731992EE-88CF-4AE0-81AD-6D2E8D22AF87 Q34092322-A9D1E238-F825-49A0-957B-CD9C9D86D859 Q34092454-795DADD1-F529-4D88-89F6-6718123D3FD8 Q34339456-770E1E25-25AB-4054-A21E-124A160485D5

P2860

Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial

http://www.wikidata.org/entity/Q28294837

description

2013 nî lūn-bûn

@nan

2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Alternative treatments to inhi ...... AN randomised controlled trial

@ast

Alternative treatments to inhi ...... AN randomised controlled trial

@en

Alternative treatments to inhi ...... AN randomised controlled trial

@nl

type

label

Alternative treatments to inhi ...... AN randomised controlled trial

@ast

Alternative treatments to inhi ...... AN randomised controlled trial

@en

Alternative treatments to inhi ...... AN randomised controlled trial

@nl

prefLabel

Alternative treatments to inhi ...... AN randomised controlled trial

@ast

Alternative treatments to inhi ...... AN randomised controlled trial

@en

Alternative treatments to inhi ...... AN randomised controlled trial

@nl

P1433

Q28294837-1A8DCFAC-DDD5-422F-8514-C303CF5CBA1D

P1476

Q28294837-99C9E554-7852-49D0-AC99-46BCC3EABD95

P2093

Q28294837-02E376C0-42DA-4BA7-9630-D1F7C9A6E9DC

Q28294837-13CE4439-E6D8-4EBB-AA47-2BBE63110659

Q28294837-9D7F03A6-3DCD-4C72-97C3-88A4D0F8B3AC

Q28294837-A157A509-81EC-4F14-9BAF-704C73A467B2

Q28294837-CCFD6107-23A0-4F7D-9696-38631D40233F

P304

Q28294837-7129E839-A453-44B3-BFE1-D02214B1686B

P31

Q28294837-3315EAD9-73C7-4A1B-B816-D19155BB285C

P3181

Q28294837-5A16586B-CBFE-4E20-A04F-75854D057283

P356

Q28294837-F3054E25-31A7-4F2F-A385-A187590979FE

P407

Q28294837-01511A78-FEBA-4D35-BF22-0F9196DCCAAF

P433

Q28294837-6981106D-115D-4E94-B07E-578A602CFE0F

P478

Q28294837-6C385B41-65FF-4290-9125-FD547189405D

P50

Q28294837-201CDB76-5F5F-4E21-910F-CB9C72F75487

Q28294837-7599B77C-DB54-4B32-90C6-E900FA3B5B47

P577

Q28294837-3658E3C9-C269-4D63-8351-3BF05C2A0566

P5875

Q28294837-1045352C-E867-43B3-AA49-4FDBB801D42D

P698

Q28294837-ADE6035B-452B-4B6B-9396-47579B6DACCD

P921

Q28294837-47072038-EB90-420D-BA1A-0DA04DA8993C

P3181

P356

S0140-6736(13)61501-9

P1433

P1476

Alternative treatments to inhi ...... AN randomised controlled trial

@en

P2093

Andrew J Lotery

http://www.w3.org/2001/XMLSchema#string

Barnaby C Reeves

http://www.w3.org/2001/XMLSchema#string

Chris A Rogers

http://www.w3.org/2001/XMLSchema#string

Lucy A Culliford

http://www.w3.org/2001/XMLSchema#string

Susan M Downes

http://www.w3.org/2001/XMLSchema#string

P304

1258-67

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1096705

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/S0140-6736(13)61501-9

http://www.w3.org/2001/XMLSchema#string

P407

P433

9900

http://www.w3.org/2001/XMLSchema#string

P478

382

http://www.w3.org/2001/XMLSchema#string

P50

Simon P. Harding

Usha Chakravarthy

P577

2013-10-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

274019586

http://www.w3.org/2001/XMLSchema#string

P698

23870813

http://www.w3.org/2001/XMLSchema#string

P921

neovascularization